38 completed, 9 unknown, 1 active not recruiting, 1 enrolling by invitation. 51 Phase 2, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 51 | Completed 38, Unknown 9, Active not recruiting 1, Enrolling by invitation 1, Recruiting 1, Terminated 1 |
| Phase 1 | 8 | Completed 4, Unknown 3, Enrolling by invitation 1 |
Follow Psoriasis Vulgaris: new trials by email Literature Review of Psoriasis Vulgaris trials Research Report on Psoriasis Vulgaris
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral and Topical Phytocannabinoids for Psoriasis Oral Cannabis Extract, Topical cannabis cream - Psoriasis Vulgaris | Phase 2 | Active not recruiting | Federal University of Latin American Integration | 37 | 2025-11-01 | 2026-09-24 |
| The Efficacy of Topical Formulation Containing Ciplukan (Physalis Angulata Linn.) on Psoriasis Vulgaris Lesions Ciplukan, Bethametasone valerate 0,1% cream - Psoriasis Vulgaris, Inflammation | Phase 1 / Phase 2 | Enrolling by invitation | Universitas Padjadjaran | 40 | 2025-02-13 | 2025-04-01 |
| Shuiniujiao Dihuang Decoction With Variation for the Treatment of Psoriasis SDD formula, Placebo - Psoriasis Vulgaris | Phase 2 | Recruiting | Chinese University of Hong Kong | 58 | 2024-06-11 | 2026-07-30 |
| Topical SGX302 for Mild-to-Moderate Psoriasis Hypericin - Psoriasis, Plaque Psoriasis | Phase 2 | Completed | Soligenix | 15 | 2022-12-14 | 2026-08-13 |
| Clinical Trial of Probiotic Supplementation in Psoriasis Vulgaris Lactobacillus Plantarum IS-10506, Placebo - Psoriasis Vulgaris | Phase 1 / Phase 2 | Unknown | Dr. Soetomo General Hospital | 75 | 2022-02-07 | 2022-02-24 |
| Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome. Triamcinolone Acetonide Acetate and Urea Cream., Qing-Re-Liang-Xue Decoction. - Psoriasis Vulgaris | Phase 2 | Unknown | The First Affiliated Hospital of Zhejiang Chinese Medical University | 200 | 2021-09-01 | 2021-08-06 |
| Oral Chinese Herbal Medicine for Psoriasis Vulgaris With Blood Stasis Syndrome Taodan Granules, Taodan Granules Placebo - Psoriasis Vulgaris | Phase 2 | Unknown | Shanghai Yueyang Integrated Medicine Hospital | 216 | 2019-06-01 | 2019-05-08 |
| Oral Chinese Herbal Medicine for Psoriasis Vulgaris With Blood Heat Syndrome Jueyin granules, Jueyin Granules Placebo - Psoriasis Vulgaris | Phase 2 | Unknown | Shanghai Yueyang Integrated Medicine Hospital | 196 | 2019-06-01 | 2019-05-23 |
| A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects MC2-01 cream - Psoriasis Vulgaris | Phase 2 | Terminated | MC2 Therapeutics | 7 | 2018-12-27 | 2021-03-19 |
| A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis PRCL-02, Placebo - Psoriasis Vulgaris, Plaque Psoriasis | Phase 2 | Completed | PRCL Research Inc. | 92 | 2018-09-25 | 2020-03-30 |
| Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin Betamethasone-Calcipotriene Topical - Psoriasis Vulgaris | Phase 2 | Completed | Centre Hospitalier Universitaire de Nice | 30 | 2018-09-24 | 2019-04-18 |
| A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream MC2-01 Cream, CAL/BDP combination - Psoriasis Vulgaris | Phase 2 | Completed | MC2 Therapeutics | 63 | 2018-02-08 | 2019-12-24 |
| Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris SNA-120, Vehicle - Pruritus, Psoriasis Vulgaris | Phase 2 | Completed | Sienna Biopharmaceuticals | 208 | 2017-10-10 | 2019-02-08 |
| Safety and Efficacy of CD10367 in Psoriasis Vulgaris CD10367 3% Solution - Non-desquamated zone, CD10367 1% Solution - Non-desquamated zone, CD10367 solution placebo - Non-desquamated zone - Psoriasis Vulgaris | Phase 2 | Completed | Galderma R&D | 24 | 2016-11-03 | 2024-09-19 |
| LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris LEO 32731, LEO 32731 Placebo - Psoriasis Vulgaris | Phase 2 | Completed | LEO Pharma | 36 | 2016-09-01 | 2017-08-28 |
| TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Treatment TAB08, Placebo - Psoriasis Vulgaris | Phase 1 / Phase 2 | Completed | Theramab LLC | 9 | 2016-04-01 | 2017-02-15 |
| Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis LEO 90100 - Psoriasis Vulgaris | Phase 2 | Completed | LEO Pharma | 117 | 2016-03-01 | 2025-03-10 |
| Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Methotrexate Methotrexate - Psoriasis Vulgaris | Phase 2 | Unknown | Central South University | 400 | 2015-12-01 | 2016-03-22 |
| Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules Acitretin Capsules - Psoriasis Vulgaris | Phase 2 | Unknown | Central South University | 500 | 2015-12-01 | 2016-03-22 |
| Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-IIb Trial) Total coumarin (TC) cream, Vehicle - Psoriasis Vulgaris, Topical Administration | Phase 2 | Completed | Psoriasis Research Institute of Guangzhou | 88 | 2015-06-11 | 2026-03-25 |
Showing 20 of 51. Sign in to see all of them.
Psoriasis (8) · Inflammation (2) · Pruritus (2) · Autoimmune Diseases (1) · Lymphoma, Follicular (1) · Marijuana Abuse (1) · Plaque, Amyloid (1) · Skin Diseases (1)
Skin and Connective Tissue Diseases (9) · Skin Diseases (8) · Skin Diseases, Papulosquamous (8) · Pathological Conditions, Signs and Symptoms (5) · Immune System Diseases (2) · Pathologic Processes (2) · Signs and Symptoms (2) · Skin Manifestations (2) · Chemically-Induced Disorders (1) · Hemic and Lymphatic Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1)
calcipotriene (8) · Gels (3) · betamethasone-17,21-dipropionate (3) · Betamethasone (2) · KD025 (2) · Ointments (2) · belumosudil (2) · 14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione (1) · 2-(6-(2-(3,5-dichloro-4-pyridyl)acetyl)-2,3-dimethoxyphenoxy)-N-propylacetamide (1) · Abatacept (1) · Acitretin (1) · Betamethasone Valerate (1) · Hydrocortisone (1) · Methotrexate (1) · Phototherapy (1)
LEO Pharma (17) · Central South University (2) · Kadmon Corporation, LLC (2) · MC2 Therapeutics (2) · Shanghai Yueyang Integrated Medicine Hospital (2) · Affiliated Hospital to Academy of Military Medical Sciences (1) · Biotest (1) · Bristol-Myers Squibb (1) · Centre Hospitalier Universitaire de Nice (1) · Chang Gung Memorial Hospital (1) · Chinese University of Hong Kong (1) · Creabilis SA (1) · Delenex Therapeutics AG (1) · Dr. Soetomo General Hospital (1) · Eisai Limited (1)
United States (16) · Canada (9) · Germany (9) · France (8) · China (6) · United Kingdom (4) · Poland (3) · Czechia (2) · Indonesia (2) · Romania (2) · Taiwan (2) · Austria (1) · Brazil (1) · Denmark (1) · Hong Kong (1)
Catherine Queille-Roussel, MD (2) · Jia Zhou (2) · Xiang Chen, MD (2) · Amy S Paller, MD (1) · Andreas Pinter, MD (1) · Chen Hu, Ph.D (1) · Colin Fleming, MD (1) · Daniil Nemenov, M.D. (1) · Dr. Harry Galuh Nugraha, dr., Sp.Rad(K) (1) · Edward Heilman, MD (1) · George Han (1) · Gottfried Wozel, Prof. Dr.med (1) · Hagit Matz, M.D. (1)
PMID 12713574, PMID 23986161, PMID 25708531, PMID 27716172, PMID 31700924, PMID 32351609, PMID 32785881, PMID 34397196
2009 (1), 2016 (1)